Recruiting
Phase 1

APG-3288

Sponsor:

Ascentage Pharma Group Inc.

Code:

NCT07424833

Conditions

Relapsed/Refractory Hematological Malignancies

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL

Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)

Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Relapsed/Refractory Waldenström Macroglobulinemia (WM)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

APG-3288

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-12. This information was provided to ClinicalTrials.gov by Ascentage Pharma Group Inc. on 2026-07-30.